4D Molecular Therapeutics (FDMT) Accumulated Depreciation (2019 - 2026)

4D Molecular Therapeutics (FDMT) has 8 years of Accumulated Depreciation data on file, last reported at $22.5 million in Q1 2026.

• Accumulated Depreciation for Q1 2026 came in at $22.5 million, up 27.86% year-over-year; the trailing twelve-month figure through Mar 2026 was $22.5 million (up 27.86% YoY), and the FY2025 annual result was $21.3 million, up 28.3% from the prior year.
• Accumulated Depreciation advanced to $22.5 million in Q1 2026 per FDMT's latest filing, from $21.3 million in the prior quarter.
• Over five years, Accumulated Depreciation peaked at $22.5 million in Q1 2026 and troughed at $5.7 million in Q1 2022.
• A 5-year average of $13.4 million and a median of $13.1 million in 2024 frame the typical range for Accumulated Depreciation.
• The sharpest annual moves came in 2023 and 2026: Accumulated Depreciation jumped 61.32% in 2023, then rose 27.86% in 2026.
• A 5-year view of Accumulated Depreciation shows it stood at $7.7 million in 2022, then jumped by 54.4% to $11.9 million in 2023, then jumped by 39.0% to $16.6 million in 2024, then rose by 28.3% to $21.3 million in 2025, then rose by 5.97% to $22.5 million in 2026.
• Business Quant data shows FDMT's Accumulated Depreciation at $22.5 million in Q1 2026, $21.3 million in Q4 2025, and $20.1 million in Q3 2025.